Accumulating evidence suggests that disruption of NAV3 contributes progression of breast cancer [32], colorectal cancer [33], T-cell lymphoma [34] and nervous system tumors including neuroblastoma [22]. The gene discussed is NAV3; the disease is T-cell non-Hodgkin lymphoma.